BJMO - , issue ,
Ronald de Wit; MD
The positive outcome of several randomized clinical trials evaluating immune checkpoint inhibitors in patients with metastatic bladder cancer dramatically changed the treatment paradigm in this setting. In his presentation, Prof. de Wit summarized the clinical data generated with PD-1/PD-L1 inhibitors in this setting, but he kicked off by summarizing the historical results obtained with chemotherapy in patients with metastatic urothelial cancer.
Read moreBJMO - volume 12, issue 10, march 2018
Ronald de Wit; MD , PhD
The positive outcome of several randomized clinical trials evaluating immune checkpoint inhibitors in patients with metastatic bladder cancer dramatically changed the treatment paradigm in this setting. In his presentation, Prof. de Wit summarized the clinical data generated with PD-1/PD-L1 inhibitors in this setting, but he kicked off by summarizing the historical results obtained with chemotherapy in patients with metastatic urothelial cancer.
Top
